Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Parasomnias 2Lung Neoplasms 2Weight Loss 1Uveal Melanoma 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Smith-Magenis Syndrome 1Sleep Wake Disorders 1Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Cancer - Female 1Barrett Esophagus 1Autism Spectrum Disorder 1Anorexia 1Angelman Syndrome 1

Interventions

Melatonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Autism Spectrum Disorder × Melatonin × Clear all
NCT01906866 2024-04-23

Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Neurim Pharmaceuticals Ltd.

Phase 3 Completed
125 enrolled 22 charts

Autism Spectrum Disorder, Sleep Wake Disorders, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔